ANDA 208869, held by Apotex Inc. Ruxolitinib.
As of Nov 16, 2026, ANDA 208869 (Ruxolitinib), held by Apotex Inc, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 9, 2026 | Original application | Tentative approval |
| Ruxolitinib10MG · tablet | Ruxolitinib | None (tentative approval) |
| Ruxolitinib15MG · tablet | Ruxolitinib | None (tentative approval) |
| Ruxolitinib20MG · tablet | Ruxolitinib | None (tentative approval) |
| Ruxolitinib25MG · tablet | Ruxolitinib | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters